Replies to post #10300 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

Waiting for revenue numbers instead of conference presentations. Expect to have major inventory write-off in the not so distant future. Exec comp will probably exceed R&D and sales expenses combined.